On Apr. 16, 2020, Moderna announced an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA), a program of the U.S. Department of HHS, to accelerate development of the Companyﾒs mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).